|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
intercalates DNA
|
|
gptkbp:appointed_by
|
intravenous injection
cancer treatment regimens
|
|
gptkbp:approves
|
gptkb:1974
gptkb:FDA
|
|
gptkbp:associated_with
|
DNA damage
anthracycline antibiotics
free radical formation
topoisomerase II inhibition
|
|
gptkbp:can_be_used_with
|
gptkb:paclitaxel
gptkb:cyclophosphamide
gptkb:trastuzumab
|
|
gptkbp:class
|
anthracycline
|
|
gptkbp:clinical_trial
|
Phase IV
Phase II
Phase III
Phase I
|
|
gptkbp:contraindication
|
pregnancy
severe liver disease
lactation
|
|
gptkbp:developed_by
|
gptkb:daunorubicin
|
|
gptkbp:discovered_by
|
NCI
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
doxorubicin
|
|
gptkbp:ingredients
|
C27 H29 O11
|
|
gptkbp:interacts_with
|
blood thinners
live vaccines
other chemotherapy drugs
|
|
gptkbp:invention
|
gptkb:2020
|
|
gptkbp:is_available_on
|
generic drug
|
|
gptkbp:is_used_for
|
treating cancer
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:produced_by
|
pharmaceutical companies
|
|
gptkbp:research_focus
|
combination therapies
drug resistance
cardiotoxicity
|
|
gptkbp:rounds
|
kidneys
|
|
gptkbp:shelf_life
|
24 months
|
|
gptkbp:side_effect
|
nausea
hair loss
heart damage
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:traded_on
|
gptkb:Adriamycin
|
|
gptkbp:used_in
|
leukemia treatment
breast cancer treatment
lymphoma treatment
sarcoma treatment
|
|
gptkbp:bfsParent
|
gptkb:methotrexate
gptkb:actinomycin_D
|
|
gptkbp:bfsLayer
|
4
|